FPR1 and colorectal carcinoma: Strong epidemiologic evidence showed that loss-of-function polymorphisms of FPR1 are positively associated with poor responses to chemotherapeutic drugs and an earlier mean age of cancer diagnosis (Sztupinszki et al., 2021) also in CRC patients.